Foundation of CL Bencard a specialist allergy company in Devon, England.
Beecham Group Ltd acquires CL Bencard, a company specialising in allergy vaccines. It is a step forward towards ethical pharmaceutical products for the Beecham company.
Bencard Allergy moves from Brockham Park to Great West Road, London and opens the "Bencard Allergy Clinic"
Bencard acquires Wright-Fleming Institute, a small vaccine manufacturing business. Introduction of Influvac (influenza vaccine).
Launch of Pollinex vaccine containing grass pollen allergens in the UK.
Launch of Pollinex vaccine containing grass pollens in Germany.
Launch of Pollinex R (Ragweed) for the Canadian market.
Launch of Mugwort, Plantain, Parietaria and Olive in Pollinex for the Southern European markets.
Launch of Tyrosine S in Germany.
Launch of Pollinex containing tree allergens in Germany and general export markets.
Launch of Oralvac, a sublingual allergy desensitising vaccine in Germany.
Ribi Immunochem Research Ltd (now Corixa) sign an agreement with SmithKline Beecham for the use of the novel adjuvant MPL in the development of allergy vaccines.
MBI acquires Bencard business from SmithKline Beecham to form Allergy Therapeutics Ltd.
Launch of Pollinex Quattro in Germany. Allergy Therapeutics sets up new markets in Italy, Spain, Czech & Slovak Republics and Poland.
Allergy Therapeutics granted patent in USA for MPL/Tyrosine/Antigen.
Allergy Therapeutics signs license deal with PLIVA, the largest pharmaceutical company in Central & Eastern Europe.
Allergy Therapeutics appoints new Board of Directors.
Financial restructuring at Allergy Therapeutics.
Allergy Therapeutics and Novartis enter into an agreement to cooperate in the commercialisation of Novartis ophthalmology product Zaditen Optha.
Launch of Oralvac Plus.
Allergy Therapeutics floats on Alternative Investment Market, London.
Allergy Therapeutics commences dosing in Phase III POLLINEX Quattro Grass study.
Pivotal Phase III Pollinex Quattro Grass study meets primary efficacy endpoint
Pivotal Phase III Pollinex Quattro Ragweed study meets primary efficacy endpoint.
European patent granted for MPL-based sublingual vaccines.
Key technology patent for Pollinex Quattro granted in Japan.
New CEO appointed and Board strengthened.
Raised £24.4 million via a placing, subscription and offer and the exercise of warrants.
Ten further Market Authorisation Applications submitted in Germany.
FDA confirmed hold would be lifted on all three investigator drugs applications for Pollinex Quattro products.
Received the complete report from PEI on its Market Authorisation Application for Grass MATA MPL.
Graass MATA MPL dossier submitted in Switzerland.
Obtained exclusive distribution rights for UK and Ireland for epinephrine pen auto injector Anapen.
Allergy Therapeutics expands into Latin America in line with emerging market strategy.
Raised £13.3 million though a placing, subscription and offer and debt.
FDA clinical hold dated 2007 was lifted on grass pollen allergy vaccine.
Appointment of new R & D Director
US patent granted for a broad technology patent relating to Allergy Therapeutics’ family of MPL-based sublingual allergy vaccines.
Publication of paper:
• A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.
• Aluminium in allergen-specific subcutaneous immunotherapy – a German perspective.
• Probiotics in the Treatment of Chronic Rhinoconjunctivitis and Chronic Rhinosinusitis.
Health Canada approves submitted clinical trial application.